

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**March 2022**

---

**Commission File Number:** 0001723069

---

**Tiziana Life Sciences LTD**

(Exact Name of Registrant as Specified in Its Charter)

---

**9<sup>th</sup> Floor  
107 Cheapside  
London  
EC2V 6DN**

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On March 1, 2022, Tiziana Life Sciences LTD (the "Company") issued a news service announcement in the United States announcing StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TIZIANA LIFE SCIENCES LTD**

Date: March 1, 2022

By: /s/ Kunwar Shailubhai

Name: Kunwar Shailubhai

Title: Chief Executive Officer

EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">News Service Announcement, dated March 1, 2022</a>

## StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

**New York, March 1, 2022** - Tiziana Life Sciences Ltd.'s (Nasdaq: TLISA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.

Investigators from the European Institute of Oncology (IEO) in Milan and The Royal Marsden Hospital in London evaluated 776 tumor samples from the TransATAC cohort, a subgroup of estrogen receptor positive (ER+), post-menopausal patients from the prospective, randomized ATAC trial. The pivotal TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including OncotypeDX, Prosigna, EndoPredict and Breast Cancer Index.

In this analysis, investigators demonstrated that patients with a StemPrintER Risk Score (SPRS) Low result had significantly better outcomes than patients with a SPRS High result. Patients with a SPRS Low result had a 5.8% risk of distant recurrence at 10 years versus 23.2% risk of distant recurrence in patients with a SPRS High result.<sup>1</sup>

“Many genomic classifiers have been evaluated in the TransATAC cohort,” said Salvatore Pece, Full Professor at the Milan University Medical School and Director of the Hormone-Related Cancers and Stem Cell Pathobiology Lab at IEO. “It is exciting that StemPrintER appears to perform as well as other commercially-available tests and indicates the potential for this novel test to inform clinical decision making.”

### Forward-Looking Statements

This press release contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Tiziana Life Sciences Ltd. assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

### Media Contact:

#### Tiziana Life Sciences Ltd

Hana Malik, Business Development, and Investor Relations Manager  
+44 (0) 207 495 2379  
email: [info@tizianalifesciences.com](mailto:info@tizianalifesciences.com)

#### Investors:

Irina Koffler  
LifeSci Advisors, LLC  
646.970.4681  
[ikoffler@lifesciadvisors.com](mailto:ikoffler@lifesciadvisors.com)

1. Pece, S., Sestak, I., Montani, F., Tillhon, M., Maisonneuve, P., Freddi, S., Chu, K., Colleoni, M., Veronesi, P., Disalvatore, D., Viale, G., Buus, R., Cuzick, J., Dowsett, M., & Di Fiore, P. P. (2022). Comparison of stemprinter with Oncotype DX recurrence score for predicting risk of breast cancer distant recurrence after endocrine therapy. *European Journal of Cancer*, 164, 52–61. <https://doi.org/10.1016/j.ejca.2022.01.003>